Guest Editors
Prof. Kyaw Zin Thein
Email: kyaw.thein@usoncology.com
Affiliation:
1. Department of Medical Oncology and Hematology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89169, USA
2. Department of Medicine, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV 89106, USA
Homepage:
Research Interests: Phase 1 (investigational cancer therapeutics), thyroid, head and neck cancers
Prof. Jo-Lawrence Martinez Bigcas
Email: jo-lawrence.bigcas@unlv.edu
Affiliation: Department of Otolaryngology-Head and Neck Surgery, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV 89106, USA
Homepage:
Research Interests: Head and neck cancer, salivary and thyroid disease, cancer prevention, skull base surgery, robotic surgery, and head and neck reconstruction
Summary
Newer immunological and targeted therapies are welcomed to the therapeutic armamentarium in treating thyroid, and head and neck cancers.
Immunotherapy for head and neck cancer has become an important part of treatment and has undergone innovative developments.
Several pieces of the puzzle are still missing when utilizing immunotherapy in head and neck squamous cell carcinoma.
Moreover, there are many trials employing immunotherapy with radiotherapy in locally advanced settings, yet results have not been universally positive.
This special Issue will cover recent newer therapeutics approvals in thyroid and head and neck cancers, the development of immunotherapy in the setting of locally advanced HNSCC and strategies to overcome it, and lessons learned from those trials.
Recent successes in targeted therapies have created an exciting new avenue in treating thyroid cancers and improving outcomes for patients with those tumors.
Keywords
Immunotherapy, targeted therapy, head and neck cancer, thyroid cancer
Login
Register
Submit a Paper
Propose a Special lssue